4 manuscripts in 2023
2 manuscripts in 2022
2 manuscripts in 2019
3 manuscripts in 2018
5 manuscripts in 2017
2023
Baldwin, H., Graber, E., Harper, J. C., Alexis, A. F., Stein Gold, L., Kircik, Del Rosso, J., Hebert, A. A., Rieder, E. A., Fried, R. G., Narayanan, S., Koscielny, V., Kasujee, I. Improvements in acne severity, symptoms and psychosocial burden among patients with non-nodular acne vulgaris administered sarecycline for 12-weeks: PROSES study. Submitted to JDD. 2023; In review.
Graber, E., Baldwin, E. A., Fried, H., Rieder, R. G., Hebert, A. A., Del Rosso, J., L., Kircik, Stein Gold, L., Harper, J. C., Alexis, A. F., Narayanan, S., Koscielny, V., Kasujee, I. (2023) Impact of acne vulgaris on social and emotional functioning and activities of daily living among patients with moderate to severe non-nodular acne vulgaris in real-world US community practices: PROSES study. Submitted to JDD. 2023; In review.
Berman, B., Armstrong, A., Lebwohl, M., Grada, A., Bhatia, N., Patel, V. A., Rigel, D., Del Rosso, J., Schlesinger, T., Kircik, L., Raidah, S. , Narayanan, S., & Kasujee, I. Developing a Questionnaire for Assessing Clinician and Patient-Reported Outcomes in Actinic Keratosis: Results From an Expert Panel. Submitted to JAAD International. 2023; In review.
Schlesinger, T., Kircik, L., Del Rosso, J., Rigel, D., Lebwohl, M., Berman, B., Armstrong, A., Bhatia, N., Patel, V. A., Narayanan, S., Koscielny, V., & Kasujee, I. Clinician- and Patient-Reported Outcomes with Tirbanibulin 1% Treatment for Actinic Keratosis in Routine Clinical Practice Across the U.S. (PROAK Study). SKIN The Journal of Cutaneous Medicine. 2023; 7(3), 771–787. Doi: 10.25251/skin.7.3.3.
2022
Narayanan S. Payer–patient engagement framework to strengthen ethical formulary decision-making in rare disease arena in the USA. Future Rare Diseases. Jan 23; 3 (1). Doi: 10.2217/frd-2022-0016.
Narayanan S. The Value of Medicines: An Investigation of Incorporation of Patient Input into Payer Decisions in the U.S. Monarch Research Paper Series. 2022, May 22; 1 (1): 1-44.
2019
Bell SC, Mainz JG, MacGregor G, Madge S, Macey J, Fridman M, Suthoff ED, Narayanan S, Kinnman N. Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: Results from a cross-sectional study. BMC Pulmonary Medicine. 2019; 19 (146).
Ng C, Kato T, Han C, Wang G, Trivedi M, Shao H, Ramesh V, Gala S, Narayanan S, Tan W, Feng Y, Kasper S. Definition of Treatment-Resistant Depression – Asia Pacific Perspectives. Journal of Affective Disorders. 2019, Feb 15; 245:626-36.
2018
Narayanan S, Privolnev, Y. Balancing expectations: An unmet need in orphan disease arena. Pharmaphorum Deep Dive Magazine. October 17, 2018.
Narayanan S. Top five: Top five factors affecting drug pricing and reimbursement and evidence landscape in 2018 and Top five factors affecting accelerated drug approvals landscape in 2018. Med Ad News. Aug 2018; p32.
Shieh PB, Mcintosh J, Jin F, Souza M, Elfring G, Narayanan S, Trifillis P, Peltz SW, Mcdonald CM, Darras BT, and the ACT DMD Study Group. Deflazacort vs Prednisone/Prednisolone for Maintaining Motor Function and Delaying Loss of Ambulation: A Post Hoc Analysis from the Act DMD Trial. Muscle and Nerve. 2018, Nov; 58(5):639-45.
2017
Roter DL, Narayanan S, Smith K, Bullman WR, Rausch P, Wolff J, Alexander C. Family Caregivers’ Facilitation of Daily Adult Prescription Medication Use. Patient Educ Couns. 2017 Dec 27. pii: S0738-3991(17)30664-X. [Epub ahead of print] (FDA Grant #5U18FD004653)
Narayanan S, Gala S. Burden of Merkel Cell Carcinoma: A Targeted Literature Review. M J Canc, 2017; 2(1):011.
Narayanan S, Black J. The Case for Greater Access for Once-Daily Single Tablet Regimens to Treat HIV Infection in Europe. M J HIV. 2017; 2(1): 013.
Narayanan S, Mainz J, Gala S, Tabori H, Grossoehm D. Adherence to Therapies in Cystic Fibrosis: A Targeted Literature Review. Exp Rev in Resp Med. 2017; 11(2):129-145.
Narayanan S. What makes physicians consider patients suitable for biosimilar infliximab. [Editorial] GaBi Online. January 27, 2017.
To request more information, send us an email at info@avant-health.com